Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
CA 2480263 A1 · Owner: Hellstrom, Karl Erik · Inventors: Ledbetter, Jeffrey A.; Hayden-Ledbetter, Martha; Hellstrom, Karl Erik
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An improved method for ex-vivo generation of tumor-reactive T cells is provided, comprising, for example, culturing PBMC from a patient with cancer with autologous tumor cells and magnetic beads that can activate T lymphocytes via CD3 in combination with CD28, CD40 or CD28 plus CD40. The invention also provides genes encoding anti-CD3 or anti-4~1BB scFv and methods to transfect cells of neoplastic or normal origin for expression of those genes at their surface. The genes and transfected tumor cells are useful compositions for induction of a tumor-destructive immune response.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 26, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 26, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 26, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.